KAPA

Kairos Pharma, Ltd.
KAPA
Market cap $18.9M

1.47 USD

-0.24

14.04%

At close Nov 19, 4:00 PM EST

After hours

1.44

-0.03

2.04%

1 day

-14.04%

5 days

-42.35%

1 month

-2.00%

3 months

-40.24%

6 months

-40.24%

Year to date

-40.24%

1 year

-40.24%

5 years

-40.24%

10 years

-40.24%

About: Kairos Pharma Ltd is a clinical-stage biopharmaceutical company. It is engaged in therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma.

0

Funds holding %

of 6,735 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

0.1% more ownership

Funds ownership: 0% [Q2] → 0.1% (+0.1%) [Q3]

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$9

512%

upside

Avg. target

$9

512%

upside

High target

$9

512%

upside

2 analyst ratings

2 positive

100%

0 neutral

0%

0 negative

0%

D. Boral Capital Jason Kolbert 17% 1-year accuracy 18 / 109 met price target	512%upside $9	Buy Maintained	14 Nov 2024
EF Hutton Jason Kolbert 17% 1-year accuracy 18 / 109 met price target	512%upside $9	Buy Initiated	14 Oct 2024

See Analyst Rankings

Financial journalist opinion

Kairos Pharma to Present at the LD Micro Main Event XVII

LOS ANGELES, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announced today that John S. Yu, M.D., Chief Executive Officer, will present a corporate overview at the LD Micro Main Event XVII. The conference is being held on October 28 – 30, 2024 at the Luxe Sunset Boulevard Hotel in Los Angeles.

Kairos Pharma to Present at the LD Micro Main Event XVII

Kairos Pharma to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

LOS ANGELES, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announced today that John S. Yu, M.D., Chief Executive Officer, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit where he will be speaking with Jason McCarthy, Ph.D., Senior Managing Director, Head of Biotechnology Research at Maxim Group. The summit is being held virtually on October 15 – 17, 2024.

Kairos Pharma to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

Kairos Pharma Enters Agreement with PreCheck Health Services to Develop Biomarkers to Identify Patients Responsive to ENV105 to Target Cancer Drug Resistance in Prostate and Lung Cancer Patients

LOS ANGELES, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announces a groundbreaking collaboration with PreCheck Health Services Inc., a CLIA-certified and CAP-accredited clinical laboratory specializing in genetic sequencing. The partnership focuses on the development of companion biomarkers for Kairos Pharma's cancer therapy, ENV105, which targets prostate and lung cancers. This strategic agreement aims to advance the precision of patient screening and therapy monitoring for Kairos Pharma's Phase 1 and Phase 2 clinical trials, with the aim of advancing cancer treatment by identifying patients who will benefit most from ENV105.

Kairos Pharma Enters Agreement with PreCheck Health Services to Develop Biomarkers to Identify Patients Responsive to ENV105 to Target Cancer Drug Resistance in Prostate and Lung Cancer Patients

U.S. IPO Weekly Recap: 2 Microcaps List As Pipeline Gets A Big Boost

Two small IPOs and two SPACs debuted this past week - Global Engine, Kairos Pharma, YHN Acquisition I, and Cayson Acquisition, respectively. Seven IPOs and three SPACs submitted initial filings. Eight companies are expected to price their IPOs in the upcoming week, including three larger deals.

U.S. IPO Weekly Recap: 2 Microcaps List As Pipeline Gets A Big Boost

Kairos Pharma Closing of $6.2 Million Initial Public Offering

LOS ANGELES, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma, Ltd. (“Kairos Pharma” or the “Company”) (NYSE American: KAPA), a clinical stage biopharmaceutical company developing cancer therapeutics designed to reverse cancer drug resistance and immune suppression, announces that it has closed its initial public offering of 1,550,000 shares of common stock at an offering price of $4.00 per share. The gross proceeds to the Company from the offering were $6,200,000, before deducting underwriting discounts and commissions and other offering expenses. The Company's common stock began trading on the NYSE American LLC on September 16, 2024 under the symbol “KAPA.”

Kairos Pharma Closing of $6.2 Million Initial Public Offering

Kairos Pharma Prices $6.2 Million Initial Public Offering

Company anticipates commencement of trading on the NYSE American effective September 16, 2024 under the symbol “KAPA” Company anticipates commencement of trading on the NYSE American effective September 16, 2024 under the symbol “KAPA”

Kairos Pharma Prices $6.2 Million Initial Public Offering

Kairos Pharma to sell 1.55 million shares in IPO at $4 each

Kairos Pharma plans to sell about 1.55 million shares in its initial public offering at $4 per share.

Kairos Pharma to sell 1.55 million shares in IPO at $4 each

See News Rankings

Charts implemented using Lightweight Charts™